IE
SLN

Israel Englander’s Silence Therapeutics SLN Stock Holding History

Israel Englander’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.98M Sell
909,279
-164,912
-15% -$1.16M ﹤0.01% 2280
2026
Q1 		$5.66M Buy
1,074,191
+414,599
+63% +$2.28M ﹤0.01% 2795
2025
Q4 		$4.01M Buy
659,592
+361,080
+121% +$2.31M ﹤0.01% 3258
2025
Q3 		$1.55M Buy
298,512
+99,865
+50% +$555K ﹤0.01% 4272
2025
Q2 		$1.15M Sell
198,647
-198,215
-50% -$850K ﹤0.01% 4299
2025
Q1 		$1.12M Sell
396,862
-76,690
-16% -$374K ﹤0.01% 4268
2024
Q4 		$3.26M Sell
473,552
-636,678
-57% -$8.22M ﹤0.01% 3221
2024
Q3 		$20.2M Buy
1,110,230
+327,289
+42% +$6.09M 0.01% 1544
2024
Q2 		$14.9M Buy
782,941
+373,523
+91% +$7.94M 0.01% 1746
2024
Q1 		$8.84M Buy
+409,418
New +$8.9M ﹤0.01% 2303
2023
Q3 		– Sell
-22,832
Closed -$126K – 6519
2023
Q2 		$126K Buy
22,832
+3,148
+16% +$19K ﹤0.01% 5272
2023
Q1 		$122K Buy
19,684
+2,248
+13% +$26.5K ﹤0.01% 5351
2022
Q4 		$266K Buy
17,436
+2,879
+20% +$37.7K ﹤0.01% 5171
2022
Q3 		$144K Buy
+14,557
New +$153K ﹤0.01% 5828

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Israel Englander's SLN Position: Q2 2026 in Review

Israel Englander reduced its Silence Therapeutics (SLN) stake by 15% in Q2 2026, selling an estimated $1.16M and leaving 909,279 shares worth $9.98M. The position accounts for ﹤0.01% of the portfolio, ranked #2280.

Israel Englander first reported a position in SLN in Q3 2022 and has held it in 14 quarters since. The position peaked at $20.2M in Q3 2024. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Israel Englander held 909,279 shares of Silence Therapeutics worth $9.98M as of Q2 2026.
  • Israel Englander sold 164,912 Silence Therapeutics shares in Q2 2026, an estimated $1.16M.
  • Silence Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2280 holding.
  • Israel Englander first reported a position in Silence Therapeutics in Q3 2022 and has held it in 14 quarters since.
  • Israel Englander's Silence Therapeutics position peaked at $20.2M in Q3 2024.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.